[{"id":"1a7e9bb9-7b86-4b0f-bf52-ec51de4a9d98","acronym":"P30CA033572","url":"https://clinicaltrials.gov/study/NCT03113500","created_at":"2021-01-18T15:20:28.612Z","updated_at":"2025-02-25T14:01:16.731Z","phase":"Phase 2","brief_title":"Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma","source_id_and_acronym":"NCT03113500 - P30CA033572","lead_sponsor":"City of Hope Medical Center","biomarkers":" ALK • TNFRSF8","pipe":" | ","alterations":" ALK positive • TNFRSF8 positive • ALK negative","tags":["ALK • TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • TNFRSF8 positive • ALK negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • etoposide IV • Adcetris (brentuximab vedotin) • prednisone • daunorubicin • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 05/25/2017","start_date":" 05/25/2017","primary_txt":" Primary completion: 07/16/2021","primary_completion_date":" 07/16/2021","study_txt":" Completion: 08/12/2025","study_completion_date":" 08/12/2025","last_update_posted":"2025-02-19"},{"id":"14db2cea-3400-48ac-8ad3-0b56fccbb5a9","acronym":"","url":"https://clinicaltrials.gov/study/NCT03007030","created_at":"2021-01-18T14:47:28.350Z","updated_at":"2025-02-25T15:42:55.122Z","phase":"Phase 2","brief_title":"Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery","source_id_and_acronym":"NCT03007030","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TNFRSF8","pipe":" | ","alterations":" TNFRSF8 positive • TNFRSF8 expression","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 positive • TNFRSF8 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Adcetris (brentuximab vedotin)"],"overall_status":"Recruiting","enrollment":" Enrollment 55","initiation":"Initiation: 04/05/2017","start_date":" 04/05/2017","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2025-02-10"},{"id":"c668d4a7-2db9-4659-a308-7bc585eaa55d","acronym":"","url":"https://clinicaltrials.gov/study/NCT02917083","created_at":"2021-01-18T14:19:13.880Z","updated_at":"2025-02-25T16:44:02.059Z","phase":"Phase 1","brief_title":"CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)","source_id_and_acronym":"NCT02917083","lead_sponsor":"Baylor College of Medicine","biomarkers":" TNFRSF8","pipe":" | ","alterations":" TNFRSF8 positive","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • TT11 • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 05/08/2017","start_date":" 05/08/2017","primary_txt":" Primary completion: 04/01/2026","primary_completion_date":" 04/01/2026","study_txt":" Completion: 02/01/2040","study_completion_date":" 02/01/2040","last_update_posted":"2025-02-05"},{"id":"e4ee9c8a-52e5-4407-8d69-cf484bfda0df","acronym":"","url":"https://clinicaltrials.gov/study/NCT01352520","created_at":"2021-01-18T05:31:44.732Z","updated_at":"2025-02-25T16:43:37.647Z","phase":"Phase 2","brief_title":"SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP)","source_id_and_acronym":"NCT01352520","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TNFRSF8","pipe":" | ","alterations":" TNFRSF8 positive • TNFRSF8 expression","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 positive • TNFRSF8 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Adcetris (brentuximab vedotin)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 79","initiation":"Initiation: 06/01/2011","start_date":" 06/01/2011","primary_txt":" Primary completion: 01/31/2026","primary_completion_date":" 01/31/2026","study_txt":" Completion: 01/31/2026","study_completion_date":" 01/31/2026","last_update_posted":"2025-02-05"},{"id":"fac97f31-c725-4a50-bd5b-feddf6e7b709","acronym":"CARCD30","url":"https://clinicaltrials.gov/study/NCT01192464","created_at":"2021-01-18T04:46:17.774Z","updated_at":"2025-02-25T16:51:03.913Z","phase":"Phase 1","brief_title":"EBV CTLs Expressing CD30 Chimeric Receptors For CD 30+ Lymphoma","source_id_and_acronym":"NCT01192464 - CARCD30","lead_sponsor":"Baylor College of Medicine","biomarkers":" TNFRSF8","pipe":" | ","alterations":" TNFRSF8 positive","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 positive"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 05/10/2011","start_date":" 05/10/2011","primary_txt":" Primary completion: 05/29/2012","primary_completion_date":" 05/29/2012","study_txt":" Completion: 10/01/2033","study_completion_date":" 10/01/2033","last_update_posted":"2025-02-04"},{"id":"0e15a431-fa68-4600-8321-5e50101e95ba","acronym":"EATL-001","url":"https://clinicaltrials.gov/study/NCT03217643","created_at":"2021-01-18T15:52:35.192Z","updated_at":"2025-02-25T14:50:36.812Z","phase":"Phase 2","brief_title":"CHP-BV Followed by Consolidation With High-dose Therapy / ASCT as Frontline Treatment of Patients With EATL Type 1.","source_id_and_acronym":"NCT03217643 - EATL-001","lead_sponsor":"Imagine Institute","biomarkers":" TNFRSF8","pipe":" | ","alterations":" TNFRSF8 positive","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Adcetris (brentuximab vedotin) • carmustine"],"overall_status":"Completed","enrollment":" Enrollment 14","initiation":"Initiation: 02/07/2018","start_date":" 02/07/2018","primary_txt":" Primary completion: 11/21/2022","primary_completion_date":" 11/21/2022","study_txt":" Completion: 05/15/2023","study_completion_date":" 05/15/2023","last_update_posted":"2024-06-19"},{"id":"531ae39e-01c4-436e-9a46-eb2502847532","acronym":"LuminICE-203","url":"https://clinicaltrials.gov/study/NCT05883449","created_at":"2023-06-01T14:07:49.446Z","updated_at":"2024-07-02T16:35:00.909Z","phase":"Phase 2","brief_title":"Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL","source_id_and_acronym":"NCT05883449 - LuminICE-203","lead_sponsor":"Affimed GmbH","biomarkers":" ALK • TNFRSF8","pipe":" | ","alterations":" ALK positive • TNFRSF8 positive • ALK negative","tags":["ALK • TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • TNFRSF8 positive • ALK negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • acimtamig (AFM13) • AFM13/AB-101 • AlloNK (GCC4001)"],"overall_status":"Recruiting","enrollment":" Enrollment 154","initiation":"Initiation: 10/10/2023","start_date":" 10/10/2023","primary_txt":" Primary completion: 04/30/2026","primary_completion_date":" 04/30/2026","study_txt":" Completion: 11/30/2027","study_completion_date":" 11/30/2027","last_update_posted":"2024-05-27"},{"id":"84dc5381-b2bd-414d-95d6-7e4b13384698","acronym":"","url":"https://clinicaltrials.gov/study/NCT01771107","created_at":"2021-01-18T07:48:13.309Z","updated_at":"2024-07-02T16:35:02.686Z","phase":"Phase 1/2","brief_title":"Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin Lymphoma","source_id_and_acronym":"NCT01771107","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TNFRSF8 • CD4","pipe":" | ","alterations":" TNFRSF8 positive","tags":["TNFRSF8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • Adcetris (brentuximab vedotin) • dacarbazine • vinblastine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 41","initiation":"Initiation: 03/07/2013","start_date":" 03/07/2013","primary_txt":" Primary completion: 10/15/2021","primary_completion_date":" 10/15/2021","study_txt":" Completion: 02/28/2025","study_completion_date":" 02/28/2025","last_update_posted":"2024-05-17"},{"id":"46916f3b-5fbd-4c36-80c3-e0c13441714b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05879458","created_at":"2023-05-30T14:05:08.419Z","updated_at":"2024-07-02T16:35:05.459Z","phase":"Phase 2","brief_title":"Ritlecitinib in CTCL","source_id_and_acronym":"NCT05879458","lead_sponsor":"Icahn School of Medicine at Mount Sinai","biomarkers":" TNFRSF8","pipe":" | ","alterations":" TNFRSF8 positive","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Litfulo (ritlecitinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 05/17/2023","start_date":" 05/17/2023","primary_txt":" Primary completion: 04/01/2026","primary_completion_date":" 04/01/2026","study_txt":" Completion: 04/01/2026","study_completion_date":" 04/01/2026","last_update_posted":"2024-05-07"},{"id":"5c8406ae-f056-4f83-9353-3927df966f6e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04774068","created_at":"2021-02-26T12:55:20.808Z","updated_at":"2024-07-02T16:35:06.559Z","phase":"Phase 1","brief_title":"Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell Lymphomas","source_id_and_acronym":"NCT04774068","lead_sponsor":"Walter Hanel","biomarkers":" TNFRSF8","pipe":" | ","alterations":" TNFRSF8 positive","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Istodax (romidepsin) • parsaclisib (INCB50465)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 5","initiation":"Initiation: 09/01/2021","start_date":" 09/01/2021","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-05-01"},{"id":"94cf6502-9e21-4ef5-8598-1f6910eb574a","acronym":"CREDIT","url":"https://clinicaltrials.gov/study/NCT05288491","created_at":"2022-03-21T19:55:51.039Z","updated_at":"2024-07-02T16:35:07.004Z","phase":"","brief_title":"A Study of Chinese Adults With Lymphoma","source_id_and_acronym":"NCT05288491 - CREDIT","lead_sponsor":"Takeda","biomarkers":" TNFRSF8","pipe":" | ","alterations":" TNFRSF8 positive • TNFRSF8 expression","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 positive • TNFRSF8 expression"],"overall_status":"Recruiting","enrollment":" Enrollment 1000","initiation":"Initiation: 10/31/2022","start_date":" 10/31/2022","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 06/30/2024","study_completion_date":" 06/30/2024","last_update_posted":"2024-04-30"},{"id":"d5dbb47e-aad4-4309-8d8b-fc01d9f10ce9","acronym":"LCCC 1606-ATL","url":"https://clinicaltrials.gov/study/NCT03602157","created_at":"2021-01-18T17:42:37.765Z","updated_at":"2024-07-02T16:35:08.204Z","phase":"Phase 1","brief_title":"Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL","source_id_and_acronym":"NCT03602157 - LCCC 1606-ATL","lead_sponsor":"UNC Lineberger Comprehensive Cancer Center","biomarkers":" TNFRSF8 • CCR4","pipe":" | ","alterations":" TNFRSF8 positive • TNFRSF8 expression","tags":["TNFRSF8 • CCR4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 positive • TNFRSF8 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bendamustine • fludarabine IV • TT11 • ATLCAR.CD30.CCR4 cells"],"overall_status":"Recruiting","enrollment":" Enrollment 59","initiation":"Initiation: 12/12/2018","start_date":" 12/12/2018","primary_txt":" Primary completion: 09/30/2026","primary_completion_date":" 09/30/2026","study_txt":" Completion: 09/30/2041","study_completion_date":" 09/30/2041","last_update_posted":"2024-04-23"},{"id":"498a1e42-e7ba-4c45-b9ea-df2809619942","acronym":"","url":"https://clinicaltrials.gov/study/NCT04074746","created_at":"2021-01-18T19:57:28.222Z","updated_at":"2024-07-02T16:35:08.805Z","phase":"Phase 1/2","brief_title":"Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas","source_id_and_acronym":"NCT04074746","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TNFRSF8","pipe":" | ","alterations":" TNFRSF8 positive","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • acimtamig (AFM13) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 07/18/2020","start_date":" 07/18/2020","primary_txt":" Primary completion: 04/15/2025","primary_completion_date":" 04/15/2025","study_txt":" Completion: 04/15/2025","study_completion_date":" 04/15/2025","last_update_posted":"2024-04-18"},{"id":"72058e45-e79d-4988-9788-961777696f7d","acronym":"","url":"https://clinicaltrials.gov/study/NCT01508312","created_at":"2021-01-18T06:20:21.000Z","updated_at":"2024-07-02T16:35:13.905Z","phase":"Phase 2","brief_title":"Brentuximab Vedotin (SGN-35) in Transplant Eligible Patients With Relapsed or Refractory Hodgkin Lymphoma","source_id_and_acronym":"NCT01508312","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" TNFRSF8","pipe":" | ","alterations":" TNFRSF8 positive","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Adcetris (brentuximab vedotin)"],"overall_status":"Completed","enrollment":" Enrollment 46","initiation":"Initiation: 01/05/2012","start_date":" 01/05/2012","primary_txt":" Primary completion: 03/14/2024","primary_completion_date":" 03/14/2024","study_txt":" Completion: 03/14/2024","study_completion_date":" 03/14/2024","last_update_posted":"2024-03-20"},{"id":"dfb86429-181f-4825-ac3d-e1a521a067ad","acronym":"","url":"https://clinicaltrials.gov/study/NCT03927105","created_at":"2021-01-18T19:20:59.843Z","updated_at":"2025-02-25T14:28:20.534Z","phase":"Phase 2","brief_title":"Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma","source_id_and_acronym":"NCT03927105","lead_sponsor":"University of Michigan Rogel Cancer Center","biomarkers":" TNFRSF8","pipe":" | ","alterations":" TNFRSF8 positive","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • cabiralizumab (BMS-986227)"],"overall_status":"Completed","enrollment":" Enrollment 4","initiation":"Initiation: 04/25/2019","start_date":" 04/25/2019","primary_txt":" Primary completion: 11/01/2019","primary_completion_date":" 11/01/2019","study_txt":" Completion: 07/06/2023","study_completion_date":" 07/06/2023","last_update_posted":"2024-03-18"},{"id":"b7ba30e7-e92c-4c59-8947-678e08f35152","acronym":"","url":"https://clinicaltrials.gov/study/NCT04288726","created_at":"2021-01-18T20:48:49.066Z","updated_at":"2024-07-02T16:35:16.521Z","phase":"Phase 1","brief_title":"Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas","source_id_and_acronym":"NCT04288726","lead_sponsor":"Baylor College of Medicine","biomarkers":" ALK • TNFRSF8","pipe":" | ","alterations":" ALK positive • TNFRSF8 positive • ALK negative","tags":["ALK • TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • TNFRSF8 positive • ALK negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TT11X"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 09/16/2020","start_date":" 09/16/2020","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2037","study_completion_date":" 06/01/2037","last_update_posted":"2024-03-04"},{"id":"9e88e211-5abf-4d40-9698-3dcf80cf1326","acronym":"","url":"https://clinicaltrials.gov/study/NCT02616965","created_at":"2021-01-18T12:42:57.122Z","updated_at":"2025-02-25T14:35:59.973Z","phase":"Phase 1","brief_title":"A Study to Assess the Feasibility of Romidepsin Combined With Brentuximab Vedotin in Cutaneous T-cell Lymphoma","source_id_and_acronym":"NCT02616965","lead_sponsor":"Fox Chase Cancer Center","biomarkers":" TNFRSF8 • CD4","pipe":" | ","alterations":" TNFRSF8 positive","tags":["TNFRSF8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Adcetris (brentuximab vedotin) • Istodax (romidepsin)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 16","initiation":"Initiation: 02/22/2017","start_date":" 02/22/2017","primary_txt":" Primary completion: 02/20/2023","primary_completion_date":" 02/20/2023","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-02-28"},{"id":"d0dd1a36-47bd-4287-8d50-49e2b6a8ce74","acronym":"REDIRECT","url":"https://clinicaltrials.gov/study/NCT04101331","created_at":"2021-01-18T20:03:46.762Z","updated_at":"2024-07-02T16:35:21.105Z","phase":"Phase 2","brief_title":"Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides","source_id_and_acronym":"NCT04101331 - REDIRECT","lead_sponsor":"Affimed GmbH","biomarkers":" TNFRSF8","pipe":" | ","alterations":" TNFRSF8 positive","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e acimtamig (AFM13)"],"overall_status":"Completed","enrollment":" Enrollment 108","initiation":"Initiation: 11/13/2019","start_date":" 11/13/2019","primary_txt":" Primary completion: 05/11/2022","primary_completion_date":" 05/11/2022","study_txt":" Completion: 01/11/2024","study_completion_date":" 01/11/2024","last_update_posted":"2024-02-02"},{"id":"5fef4db7-7b60-44eb-a4dd-40058c1475c0","acronym":"","url":"https://clinicaltrials.gov/study/NCT04587687","created_at":"2021-01-18T21:53:04.529Z","updated_at":"2024-07-02T16:35:22.744Z","phase":"Phase 2","brief_title":"Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma","source_id_and_acronym":"NCT04587687","lead_sponsor":"Joseph Tuscano","biomarkers":" TNFRSF8 • CD4","pipe":" | ","alterations":" TNFRSF8 positive","tags":["TNFRSF8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Adcetris (brentuximab vedotin) • bendamustine • Belrapzo (bendamustine RTD)"],"overall_status":"Recruiting","enrollment":" Enrollment 23","initiation":"Initiation: 12/04/2020","start_date":" 12/04/2020","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2024-01-22"},{"id":"a26e5b9a-b36c-4441-8479-38c9f9560082","acronym":"","url":"https://clinicaltrials.gov/study/NCT04213209","created_at":"2021-01-18T20:31:00.499Z","updated_at":"2024-07-02T16:35:23.367Z","phase":"","brief_title":"Special Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion \"Relapsed or Refractory CD30-positive Peripheral T Cell Lymphoma or Pediatric Hodgkin Lymphoma\"","source_id_and_acronym":"NCT04213209","lead_sponsor":"Takeda","biomarkers":" TNFRSF8","pipe":" | ","alterations":" TNFRSF8 positive","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Adcetris (brentuximab vedotin)"],"overall_status":"Completed","enrollment":" Enrollment 95","initiation":"Initiation: 12/31/2019","start_date":" 12/31/2019","primary_txt":" Primary completion: 12/13/2023","primary_completion_date":" 12/13/2023","study_txt":" Completion: 12/13/2023","study_completion_date":" 12/13/2023","last_update_posted":"2024-01-15"},{"id":"addf5c9c-8709-488b-94df-b5dfe1dd3188","acronym":"","url":"https://clinicaltrials.gov/study/NCT03729609","created_at":"2021-01-18T18:16:23.346Z","updated_at":"2024-07-02T16:35:23.380Z","phase":"","brief_title":"Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion \"Untreated CD30-Positive Hodgkin's Lymphoma\"","source_id_and_acronym":"NCT03729609","lead_sponsor":"Takeda","biomarkers":" TNFRSF8","pipe":" | ","alterations":" TNFRSF8 positive","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Adcetris (brentuximab vedotin)"],"overall_status":"Completed","enrollment":" Enrollment 113","initiation":"Initiation: 11/01/2018","start_date":" 11/01/2018","primary_txt":" Primary completion: 09/27/2023","primary_completion_date":" 09/27/2023","study_txt":" Completion: 09/27/2023","study_completion_date":" 09/27/2023","last_update_posted":"2024-01-15"},{"id":"98dc230c-608b-4b96-98ca-93699a4a09ae","acronym":"","url":"https://clinicaltrials.gov/study/NCT05414500","created_at":"2022-06-10T12:58:47.286Z","updated_at":"2024-07-02T16:35:25.996Z","phase":"Phase 1","brief_title":"Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides","source_id_and_acronym":"NCT05414500","lead_sponsor":"University of Alabama at Birmingham","biomarkers":" TNFRSF8","pipe":" | ","alterations":" TNFRSF8 positive","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Adcetris (brentuximab vedotin) • Poteligeo (mogamulizumab-kpkc)"],"overall_status":"Recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 05/01/2023","start_date":" 05/01/2023","primary_txt":" Primary completion: 12/30/2024","primary_completion_date":" 12/30/2024","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2023-12-18"},{"id":"77b4dda1-d8d4-4bef-a4ce-d026a053268b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05481437","created_at":"2022-08-01T15:55:26.465Z","updated_at":"2024-07-02T16:35:27.435Z","phase":"","brief_title":"A Survey of Brentuximab Vedotin in Pediatric Participants With Hodgkin Lymphoma","source_id_and_acronym":"NCT05481437","lead_sponsor":"Takeda","biomarkers":" TNFRSF8","pipe":" | ","alterations":" TNFRSF8 positive","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • Adcetris (brentuximab vedotin)"],"overall_status":"Recruiting","enrollment":" Enrollment 8","initiation":"Initiation: 08/01/2022","start_date":" 08/01/2022","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2023-12-01"},{"id":"be899dea-3910-43ec-86a3-34ee93b70ce2","acronym":"OSU-17204","url":"https://clinicaltrials.gov/study/NCT03409432","created_at":"2021-01-18T16:49:16.526Z","updated_at":"2024-07-02T16:35:31.071Z","phase":"Phase 2","brief_title":"Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma","source_id_and_acronym":"NCT03409432 - OSU-17204","lead_sponsor":"John Reneau","biomarkers":" TNFRSF8","pipe":" | ","alterations":" TNFRSF8 positive","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • Adcetris (brentuximab vedotin)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 26","initiation":"Initiation: 03/16/2018","start_date":" 03/16/2018","primary_txt":" Primary completion: 04/30/2024","primary_completion_date":" 04/30/2024","study_txt":" Completion: 04/30/2024","study_completion_date":" 04/30/2024","last_update_posted":"2023-10-31"}]